Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-01

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy and concurrent anti-PD-1 antibody treatment in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) in non-irradiated lesions, and incidence of adverse events (AEs).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)

NCT06313190

Hepatocellular Carcinoma

RECRUITING PHASE2

To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors

NCT02410174

Primary Tumor Renal Cell Carcinoma

TERMINATED PHASE1

SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases

NCT05577052

NSCLC

UNKNOWN NA

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery

NCT01892930

Recurrent Renal Cell Cancer Stage IV Renal Cell Cancer

COMPLETED NA

Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis

NCT06582940

MRI-guided Adaptive Radiotherapy Non-small Cell Lung Cancer Brain Metastasis

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age≥18 years at the time of signing informed consent;
* Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8);
* Previously received SBRT and concurrent PD-1 blockade treatment；
* Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria.